Merck’s $1.3 Billion Silence Therapeutics Deal Highlights Transaction-Compliance Needs

On 19 October, Merck KGaA agreed to acquire Silence Therapeutics in a transaction with an approximate $1.3 billion equity value. The all-cash offer remains subject to customary closing conditions, making due diligence, transaction documentation and regulatory processes important parts of the proposed acquisition. Legal advisers and compliance teams can explore opportunities in document management, due-diligence workflows and governance reporting. HPC can support secure data systems and document analytics; contact HPC for a quotation on suitable technology solutions.